Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update
Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol “CELU” on July 19, 2021 Clinical pipeline includes multiple clinical...
Celularity Founder, Chairman and Chief Executive Officer, Robert J. Hariri, M.D., Ph.D., Dually Awarded for Pioneering Contributions in Medicine and Leadership
The Brain Mapping Foundation and the Society for Brain Mapping and Therapeutics to celebrate this trailblazing scientist, surgeon, visionary leader and serial entrepreneur at the 18th Annual Gathering for the...
Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products
Arthrex to receive exclusive rights to distribute and commercialize Celularity’s placental-derived biomaterial products for orthopedics and sport medicine in the United States FLORHAM PARK, NJ, and NAPLES, FL, July 01,...
Celularity Announces Expansion of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) Phase 1 Trial in Patients with Acute Myeloid Leukemia
No dose limiting toxicity to date with outpatient administration of three doses (Days 0, 7 and 14) at total dose levels of 1.8, 3.6, and 5.4 Billion CYNK-001 cells, respectively...
Celularity Appoints Bradley Glover, Ph.D. as Executive Vice President and Chief Technology Officer
Pharmaceutical industry veteran brings more than 20 years of business and technical operations experience across various commercial and development products FLORHAM PARK, N.J., – May 20, 2021 — Celularity Inc. (“Celularity”),...